Dyadic Announces Robert Burke Resignation
19 Januar 2016 - 10:30PM
Dyadic International, Inc. (OTCQX:DYAI) (“Dyadic”) announced today
that Robert D. Burke, MD has resigned from the Board of Directors
of Dyadic (the 'Board') and all related board committees to which
he served which included the compensation, and nominating
committees of the board effective January 18, 2016.
Dr. Burke has served on Dyadic’s board of
directors since June 2008. "We appreciate Robert’s leadership and
his contributions over the past eight years as the company has
undergone a successful transformation and in helping guide the
company through the sale of Dyadic’s Industrial Biotechnology
business to DuPont’s (NYSE:DD) Industrial Biosciences for $75
Million," said Michael Tarnok, Dyadic’s Chairman. Mr. Tarnok
further commented that, "The Board and management of Dyadic would
like to thank Robert for his service to Dyadic and we wish him well
in his future business endeavors."
"I am proud of our accomplishments over the past
eight years and I am grateful for the support I've received from
the Board of Directors and the management team. Dyadic is now well
financed and positioned to expand its presence in
biopharmaceutical’s and I plan on remaining a shareholder,” said
Dr. Burke.
About Dyadic International,
Inc.
Dyadic International, Inc. is a global
biotechnology company which uses patented, licensed and proprietary
technologies to conduct research, development and commercial
activities for the development and manufacturing of human and
animal vaccines, monoclonal antibodies, biosimilars and/or
biobetters, and other therapeutic proteins. Dyadic utilizes
an integrated technology platform based on the patented and
proprietary strains of the C1 microorganism, which enables the
development and large scale manufacture of low cost proteins.
Dyadic believes that the C1 technology platform has potential to be
a safe and efficient expression system that may help speed up the
development and production of biologics at flexible commercial
scales. In particular, as the aging population grows in developed
and undeveloped countries, Dyadic believes C1 may help bring
biologic drugs to market faster, in greater volumes and at lower
cost to drug developers and manufacturers and, hopefully, to
patients and the healthcare system. Dyadic pursues research &
development collaborations, licensing arrangements and other
commercial opportunities to leverage the value of its technologies
by providing its partners and collaborators with the benefits of
developing and manufacturing and/or utilizing the
biopharmaceuticals which these technologies help produce. Please
visit Dyadic’s website at www.dyadic.com for additional
information, including details regarding Dyadic’s plans for its
biopharmaceutical business.
Dyadic trades on the OTCQX tier of the OTC
marketplace. Investors can find real-time quotes, market
information and financial reports for Dyadic, as well as additional
information related to its professional liability lawsuit, in the
company’s annual and quarterly reports which are filed with the OTC
markets. Please visit the OTC markets website at
www.otcmarkets.com/stock/DYAI/quote.
Safe Harbor Regarding Forward-Looking
Statements
Certain statements contained in this press
release are forward-looking statements within the meaning of the
federal securities laws. These forward-looking statements involve
risks, uncertainties and other factors that could cause Dyadic’s
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Investors
are urged to consider these factors carefully in evaluating the
forward-looking statements and are cautioned not to place undue
reliance on such forward-looking statements. Any forward-looking
statements speak only as of the date of this press release and,
except as required by law, Dyadic expressly disclaims any intent or
obligation to update or revise any forward-looking statements to
reflect actual results, any changes in expectations or any change
in events. Factors that could cause results to differ materially
include, but are not limited to: (1) general economic conditions,
including the recent conditions in the global markets; (2) Dyadic’s
ability to retain and attract employees; (3) competitive pressures
and reliance on key customers and collaborators; (4) Dyadic’s
research and development efforts, (5) the outcome of the current
litigation by Dyadic against its former counsel, (6) Dyadic’s
ability to obtain additional debt or equity financing sources and
(7) other factors discussed in Dyadic’s publicly available filings,
including information set forth under the caption “Risk Factors” in
our December 31, 2014 Annual Report filed with OTC Markets on March
27, 2015. New risks and uncertainties arise from time to time, and
it is impossible for us to predict these events or how they may
affect us.
Contact:
Dyadic International, Inc.
Mark A. Emalfarb
Chief Executive Officer
561-743-8333
DuPont de Nemours (NYSE:DD)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
DuPont de Nemours (NYSE:DD)
Historical Stock Chart
Von Jul 2023 bis Jul 2024